Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- 4682-48-8 11025-26-6 477934-03-5 4682-48-8 125712-73-4 CDH ?-D-lactoside LMCDH-1 LMCDH1 N-lignoceroyl-1-sphingosyl IL6 MIP1b MIP1? lactocerebroside Ceramide ?-lactoside CDw17 Antigen Cytolipin H Ganglioside GA3 GL2a proinflammatory MCP1
- Product Overview:
Lactosylceramide (LacCer) is an endogenous bioactive sphingolipid. It is expressed on the plasma membrane of human phagocytes and mediates phagocytosis, chemotaxis, and superoxide generation.{41044} LacCer forms membrane microdomains with Lyn kinase and the ?i subunits of inhibitory G protein-coupled receptors, suggesting a role in cell signaling. Elevated LacCer levels in kidney cortex homogenates and urine are directly correlated with hyperglycemia, insulin resistance, and obesity in db/db transgenic diabetic mice.{41045} It promotes recruitment of CNS-infiltrating monocytes and microglia and enhances neurodegeneration in mice with chronic experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS).{27728} Increased levels of LacCer in atherosclerotic plaques are correlated with increased levels of the pro-inflammatory cytokines IL-6, monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1? (MIP-1?), as well as lipids and macrophages.{41046} LacCer is also upregulated during the secretory phase of the menstrual cycle.{41047} This product contains lactosylceramide molecular species with primarily C22:0, C24:0, and 2-hydroxy C24:0 fatty acyl chain lengths. As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1500]
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.